ABBV vs. HLN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ABBV and HLN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
ABBV is a standard domestic listing, while HLN trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | ABBV | HLN |
|---|---|---|
| Company Name | AbbVie Inc. | Haleon plc |
| Country | United States | United Kingdom |
| GICS Sector | Health Care | Consumer Staples |
| GICS Industry | Biotechnology | Personal Care Products |
| Market Capitalization | 406.64 billion USD | 39.67 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | January 2, 2013 | July 25, 2022 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of ABBV and HLN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ABBV | HLN |
|---|---|---|
| 5-Day Price Return | -0.58% | 0.24% |
| 13-Week Price Return | 22.68% | -12.33% |
| 26-Week Price Return | 11.60% | -15.33% |
| 52-Week Price Return | 17.77% | -12.12% |
| Month-to-Date Return | -0.58% | -0.33% |
| Year-to-Date Return | 29.54% | -12.22% |
| 10-Day Avg. Volume | 7.35M | 17.26M |
| 3-Month Avg. Volume | 5.73M | 15.00M |
| 3-Month Volatility | 24.02% | 19.34% |
| Beta | 0.36 | 0.45 |
Profitability
Return on Equity (TTM)
ABBV
95.59%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, ABBV’s Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
HLN
3.26%
Personal Care Products Industry
- Max
- 33.29%
- Q3
- 19.04%
- Median
- 10.69%
- Q1
- 3.26%
- Min
- -10.45%
HLN’s Return on Equity of 3.26% is on par with the norm for the Personal Care Products industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
ABBV
6.45%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
HLN
12.84%
Personal Care Products Industry
- Max
- 14.65%
- Q3
- 10.84%
- Median
- 9.29%
- Q1
- 5.35%
- Min
- -0.14%
A Net Profit Margin of 12.84% places HLN in the upper quartile for the Personal Care Products industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
ABBV
18.80%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
HLN
19.64%
Personal Care Products Industry
- Max
- 19.64%
- Q3
- 16.46%
- Median
- 12.80%
- Q1
- 8.01%
- Min
- 2.98%
An Operating Profit Margin of 19.64% places HLN in the upper quartile for the Personal Care Products industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ABBV | HLN |
|---|---|---|
| Return on Equity (TTM) | 95.59% | 3.26% |
| Return on Assets (TTM) | 2.73% | 1.58% |
| Net Profit Margin (TTM) | 6.45% | 12.84% |
| Operating Profit Margin (TTM) | 18.80% | 19.64% |
| Gross Profit Margin (TTM) | 70.93% | 60.75% |
Financial Strength
Current Ratio (MRQ)
ABBV
0.74
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
ABBV’s Current Ratio of 0.74 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
HLN
0.87
Personal Care Products Industry
- Max
- 4.03
- Q3
- 2.73
- Median
- 1.76
- Q1
- 1.16
- Min
- 0.76
HLN’s Current Ratio of 0.87 falls into the lower quartile for the Personal Care Products industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
ABBV
49.22
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
HLN
0.53
Personal Care Products Industry
- Max
- 1.80
- Q3
- 0.78
- Median
- 0.30
- Q1
- 0.04
- Min
- 0.00
HLN’s Debt-to-Equity Ratio of 0.53 is typical for the Personal Care Products industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
ABBV
2.70
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
HLN
8.00
Personal Care Products Industry
- Max
- 96.53
- Q3
- 59.91
- Median
- 22.25
- Q1
- 7.85
- Min
- -3.28
HLN’s Interest Coverage Ratio of 8.00 is positioned comfortably within the norm for the Personal Care Products industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ABBV | HLN |
|---|---|---|
| Current Ratio (MRQ) | 0.74 | 0.87 |
| Quick Ratio (MRQ) | 0.48 | 0.63 |
| Debt-to-Equity Ratio (MRQ) | 49.22 | 0.53 |
| Interest Coverage Ratio (TTM) | 2.70 | 8.00 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ABBV
2.74%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ABBV’s Dividend Yield of 2.74% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
HLN
0.72%
Personal Care Products Industry
- Max
- 4.99%
- Q3
- 2.70%
- Median
- 1.98%
- Q1
- 0.95%
- Min
- 0.00%
HLN’s Dividend Yield of 0.72% is in the lower quartile for the Personal Care Products industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
Dividend Payout Ratio (TTM)
ABBV
226.84%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
HLN
954.40%
Personal Care Products Industry
- Max
- 221.40%
- Q3
- 137.27%
- Median
- 70.48%
- Q1
- 51.10%
- Min
- 0.00%
At 954.40%, HLN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Personal Care Products industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
Dividend at a Glance
| Symbol | ABBV | HLN |
|---|---|---|
| Dividend Yield (TTM) | 2.74% | 0.72% |
| Dividend Payout Ratio (TTM) | 226.84% | 954.40% |
Valuation
Price-to-Earnings Ratio (TTM)
ABBV
109.81
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
At 109.81, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
HLN
20.46
Personal Care Products Industry
- Max
- 46.28
- Q3
- 31.71
- Median
- 22.50
- Q1
- 20.20
- Min
- 11.79
HLN’s P/E Ratio of 20.46 is within the middle range for the Personal Care Products industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
ABBV
7.08
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
ABBV’s P/S Ratio of 7.08 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
HLN
2.63
Personal Care Products Industry
- Max
- 2.59
- Q3
- 2.35
- Median
- 1.92
- Q1
- 1.18
- Min
- 0.00
With a P/S Ratio of 2.63, HLN trades at a valuation that eclipses even the highest in the Personal Care Products industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
Price-to-Book Ratio (MRQ)
ABBV
261.01
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
HLN
2.11
Personal Care Products Industry
- Max
- 12.00
- Q3
- 6.22
- Median
- 2.84
- Q1
- 1.70
- Min
- 1.12
HLN’s P/B Ratio of 2.11 is within the conventional range for the Personal Care Products industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | ABBV | HLN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 109.81 | 20.46 |
| Price-to-Sales Ratio (TTM) | 7.08 | 2.63 |
| Price-to-Book Ratio (MRQ) | 261.01 | 2.11 |
| Price-to-Free Cash Flow Ratio (TTM) | 22.66 | 13.72 |